Home › Compound Library › Lansoprazole (Prevacid)

Lansoprazole (Prevacid)

Proton Pump Inhibitorprescriptionoral · predicted

Substituted benzimidazole proton pump inhibitor. Irreversibly inhibits gastric H+/K+-ATPase. Slightly faster onset than omeprazole. Metabolized by CYP2C19 and CYP3A4. Available as delayed-release capsule and orally disintegrating tablet (Solutab), useful for patients with dysphagia or NG tube administration. Used for GERD, duodenal/gastric ulcers, and H. pylori triple therapy.

Projected serum levels — 30 mg, once daily

Lansoprazole (Prevacid)
Lansoprazole (Prevacid) modeled serum levels, 30 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 30 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 18.3 mg, trough ≈ 0.22 mg body load. Population-based estimate over 15 days for a 30 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Proton Pump Inhibitor
Route modeled
Oral
Model confidence
predicted
Half-life
1.5 h
Common dose
30 mg
Suggested maximum
60 mg/day
Reference dose range
15–60 mg (single dose)
Suggested cadence
once daily
Validated against
30 mg oral — Cmax 0.80 mg/L at 1.7 h

Documented interactions

  • danger
    Carbamazepine (Tegretol) + Lansoprazole (Prevacid) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Lansoprazole (Prevacid) AUC by ~0.49x

  • danger
    CBD (Cannabidiol) + Lansoprazole (Prevacid) CYP inhibition

    CBD (Cannabidiol) reversible_inhibitor of CYP2C19 predicted to change Lansoprazole (Prevacid) AUC by ~2.07x

  • danger
    Efavirenz (Sustiva) + Lansoprazole (Prevacid) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Lansoprazole (Prevacid) AUC by ~0.35x

  • danger
    Esomeprazole (Nexium) + Lansoprazole (Prevacid) CYP inhibition

    Esomeprazole (Nexium) reversible_inhibitor of CYP2C19 predicted to change Lansoprazole (Prevacid) AUC by ~2.07x

  • danger
    Ethinyl Estradiol + Lansoprazole (Prevacid) CYP inhibition

    Ethinyl Estradiol reversible_inhibitor of CYP2C19 predicted to change Lansoprazole (Prevacid) AUC by ~2.07x

  • danger
    Fluconazole + Lansoprazole (Prevacid) CYP inhibition

    Fluconazole reversible_inhibitor of CYP2C19 predicted to change Lansoprazole (Prevacid) AUC by ~2.07x

Serum checks 242 modeled interaction pairings for lansoprazole (prevacid) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Lansoprazole versus omeprazole in short-term treatment of reflux esophagitis: a multicentre study Mulder CJ et al. · Alimentary Pharmacology & Therapeutics, 1996 DOI

    Multicenter RCT finding lansoprazole 30 mg and omeprazole 20 mg equally effective for reflux esophagitis healing (85% vs 82% at 8 weeks), with comparable symptom relief and safety profiles.

  2. Clinical pharmacokinetics of lansoprazole Langtry HD, Wilde MI · Clinical Pharmacokinetics, 1997 DOI

    PK review establishing lansoprazole half-life of 1.3-1.7 hours, 80-85% bioavailability (decreases with food), CYP2C19/3A4 dual metabolism, and rapid onset of acid suppression within 1 hour.

2 published studies referenced in the app, each with a plain-language summary.